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ABSTRACT
Background The coronavirus pandemic has provoked 
discussions among healthcare providers how to manage 
cancer patients when faced with the threat of severe acute 
respiratory syndrome related coronavirus 2 (SARS- CoV-2) 
infection. Immune checkpoint inhibitor (ICI) containing 
regimens are standard of care in the majority of metastatic 
clear cell renal cell carcinoma (mccRCC) patients. It 
remains unclear whether therapies should be modified in 
response to the COVID-19 pandemic.
Methods We performed an online survey among 
physicians involved in the treatment of mccRCC, and 41 
experts responded. Questions focused on criteria relevant 
for treatment decision outside the pandemic and the 
modifications of systemic therapy during COVID-19.
Findings For the majority of experts (73%), the 
combination of International metastatic renal cell 
carcinoma Database Consortium (IMDC) risk category 
and patient fitness are two important factors for decision- 
making. The main treatment choice in fit, favourable risk 
patients outside the pandemic is pembrolizumab/axitinib 
for 53%, avelumab/axitinib, sunitinib or pazopanib for 
13% of experts each. During the pandemic, ICI- containing 
regimens are chosen less often in favour of a tyrosine 
kinase inhibitors (TKI) monotherapy, mainly sunitinib or 
pazopanib (35%).
In fit, intermediate/poor- risk patients outside the 
pandemic, over 80% of experts choose ipilimumab/
nivolumab, in contrast to only 41% of physicians during 
COVID-19, instead more TKI monotherapies are given. In 
patients responding to established therapies with ICI/ICI or 
ICI/TKI combinations, most participants modify treatment 
regimen by extending cycle length, holding one ICI or even 
both.
Conclusion mccRCC treatment modifications in light of 
the coronavirus pandemic are variable, with a shift from 
ICI/ICI to ICI/TKI or TKI monotherapy.
INTRODUCTION
The coronavirus pandemic has substantial 
impact on public life all over the world. Since 
the onset of the pandemic,1 reports have 
been published on the adverse outcome of 
cancer patients with COVID-19.2 3 This has 
provoked discussions among healthcare 
providers how to manage cancer patients 
when faced with the threat of severe acute 
respiratory syndrome related coronavirus 2 
(SARS- CoV-2) infection and strategies were 
proposed to mitigate the hazard. In response 
to the COVID-19 pandemic, oncological 
Key questions
What is already known about this subject?
 ► The COVID-19 pandemic has substantial impact on 
public life and health care delivery all over the world. 
Among others, the benefit/risk ratio of cancer treat-
ment needs to be reconsidered. Immune checkpoint 
inhibitor (ICI) containing regimens are standard of 
care in the majority of metastatic clear cell renal 
cell carcinoma (mccRCC) patients. It remains un-
clear whether and how mccRCC therapies should be 
modified in response to the pandemic.
What does this study add?
 ► We performed an online survey among kidney can-
cer experts with the aim to ascertain their treat-
ment algorithm outside and during the coronavirus 
pandemic. The degree of impact on each health 
system is variable as the infection struck countries 
at different times and may have caused resource 
constraints. Hence, attitudes towards mccRCC 
treatment modifications diverge. The most common 
adaptations in response to the pandemic are avoid-
ance of one or two ICI and use of a tyrosine kinase 
inhibitor (TKI) monotherapy instead. In patients re-
sponding to established therapies with ICI/ICI or ICI/
TKI combinations most experts change treatment 
regimens by extending cycle length, holding one ICI 
or even both.
How might this impact on clinical practice?
 ► The results of our survey may provide some guid-
ance in the context of mccRCC treatment and 
SARS- CoV-2. In particular, we would like to raise 
awareness to the many uncertainties on the inter-
play of ICI and viral infections, outcome of cancer 
patients with SARS- CoV-2 and whether modifica-
tions in systemic therapy during the pandemic alter 
long term mccRCC patient outcome.
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societies have issued practice information and guid-
ance.4 ESMO recommends discussion of the benefits and 
risks of palliative therapy in the setting of the COVID-19 
pandemic and local constraints, weighing in all relevant 
factors: disease prognosis, patient comorbidities and pref-
erences, probability and risks from COVID-19 infection. 
Considerations should be given to drug holidays, regi-
mens and schedules that reduce the number of hospital 
visits during the pandemic (once weekly as opposed to 
thrice or twice weekly, oral or subcutaneous alternatives 
as opposed to intravenous administration). In addition, 
ESMO issued specific priorities for several cancer types5 
and published management- adapted and treatment- 
adapted recommendations for renal cell carcinoma.6
Treatment of metastatic clear cell renal cell carci-
noma (mccRCC) has advanced substantially during the 
past decade. Multiple tyrosine kinase inhibitors (TKI) 
and the monoclonal antibody bevacizumab, targeting 
either the vascular endothelial growth factor (VEGF) 
and VEGF receptors (VEGF- R), or the mammalian target 
of rapamycin pathways have been shown to significantly 
improve progression- free survival and/or even overall 
survival (OS), respectively.7–12 Four randomised trials 
have recently established combination treatment of 
either two immune checkpoint inhibitors (ICI) or an 
ICI/VEGF/VEGF- R- targeted combination: ipilimumab 
and nivolumab in CheckMate 214,13 pembrolizumab and 
axitinib in KEYNOTE-426,14 avelumab and axitinib in 
JAVELIN Renal 10115 and atezolizumab in combination 
with bevacizumab in IMmotion151.16 So far, an improve-
ment in OS has been demonstrated for ipilimumab/
nivolumab and pembrolizumb/axitinib versus sunitinib. 
In summary, ICI- containing regimens are considered 
standard of care in the majority of mccRCC patients today.
To explore the immediate response of physicians 
treating patients with mccRCC to the COVID-19 
pandemic, we performed an online survey. The aim 
of this study is to assess if and how experts in the field 
modify their first- line treatment in light of the COVID-19 
pandemic and to reflect about these changes.
METHOD
We constructed a short online questionnaire. The survey 
was sent to 85 medical oncologists and urologists who 
were selected from peer- reviewed publications in the 
field of mccRCC, site leads of the International Metastatic 
Renal Cell Carcinoma (mRCC) Database Consortium 
(IMDC) and previous personal collaborations.17 Ques-
tions were derived from practical discussions and consid-
erations when preparing oncology services for the coro-
navirus pandemic. Participants were asked introductory 
questions about affiliation and number of new mccRCC 
patients seen per year. Participants were asked about the 
importance of the following criteria for mccRCC first- 
line treatment decisions: IMDC risk category (favourable 
vs intermediate/poor risk), programmed death- ligand 
1 (PD- L1) status (PD- L1 high/positive, PD- L1 low/
negative) and patients’ fitness (fit=performance status 
(PS) 0–1, unfit=PS >1). Depending on the chosen criteria, 
a set of tailored questions followed on treatment selec-
tion outside and during the COVID-19 pandemic. Prede-
fined therapy options included: ipilimumab/nivolumab, 
pembrolizumab/axitinib, avelumab/axitinib, pazopanib 
or sunitinib, tivozanib and cabozantinib. Finally, we 
explored possible treatment modifications in patients 
responding to previously chosen mccRCC drugs.
Data collected were descriptively summarised by 
frequency and proportions. Paired samples were 
compared using McNemar’s test. Exact p value was 
reported and statistical significance was set at p value 
<0.05. SAS V.9.4 (SAS Institute) was used for analyses.
RESULTS
From 4 April 2020 to 15 April 2020, a total of 85 medical 
experts were contacted by e- mail and asked to partic-
ipate in this survey. Forty- one of 85 experts responded. 
Not every question was answered by each participant. 
Twenty- nine participants (71%) are based in Europe, 10 
(24%) in North America and 1 (3%) in Asia Pacific and 
Israel, respectively. Eighteen (44%) physicians treat more 
than 50 new patients with mRCC per year, 10 (24%) treat 
20–50 patients, 12 (29%) treat 10–20 patients and 1 (2%) 
treats 0–10 patients per year.
IMDC risk category is considered relevant by 38 (93%), 
patients’ fitness is relevant for 36 (88%) and PD- L1 status 
is relevant only for 6 (15%) experts. All three factors are 
used by six participants, while none of these factors influ-
ences their treatment choice for two physicians.
For the majority, the combination of IMDC risk category 
and patient fitness are two important factors for decision- 
making (30, 73%). The treatment choice in fit and favour-
able risk patients outside the coronavirus pandemic 
is pembrolizumab/axitinib for 16 (53%), avelumab/
axitinib and sunitinib or pazopanib for 4 (13%) each, 
ipilimumab/nivolumab for 3 (10%), tivozanib for 2 (7%) 
participants and cabozantinib for 1 (3%), respectively. 
During the COVID-19 pandemic, ICI- containing regi-
mens are chosen less often (11 (38%) pembrolizumab/
axitinib, 2 (7%) ipilimumab/nivolumab) in favour of a 
TKI monotherapy (19 (35%) sunitinib or pazopanib, 5 
(17%) tivozanib and 1 (4%) cabozantinib) (figure 1).
The difference in use of sunitinib or pazopanib outside 
and during COVID-19 is statistically significant (p<0.001).
In fit and intermediate/poor- risk patients outside the 
coronavirus pandemic, over 80% of experts (eighteen) 
choose ipilimumab/nivolumab and 18% (five) choose 
pembrolizumab/axitinib. During the pandemic, only 11 
physicians (41%) still treat with ipilimumab/nivolumab. 
Pembrolizumab/axitinib use increases to eight (30%), and 
a TKI monotherapy is recommended by one- third of physi-
cians: three (11%) sunitinib or pazopanib, three (11%) 
tivozanib and two (7%) cabozantinib. The change with 
respect to ipilimumab/nivolumab use outside and during 
the pandemic is statistically significant (p<0.001). In unfit 
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and intermediate/poor- risk patients, treatment recom-
mendations are diverse: ipilimumab/nivolumab 32% (9 
experts), cabozantinib 21% (6), pembrolizumab/axitinib 
18% (5) and sunitinib/pazopanib or tivozanib 14% (4), 
respectively. Only small changes are seen during corona-
virus pandemic (figure 2).
The group of participants who consider all three criteria 
relevant for treatment choice (IMDC, fitness and PD- L1) 
treat favourable risk patients mainly with pembrolizumab/
axitinib, some with ipilimumab/nivolumab and one with 
avelumab/axitinib. During the pandemic, a TKI mono-
therapy is used more often. In intermediate/poor- risk 
patients, only ipilimumab/nivolumab (mainly in patients 
with high PD- L1) or pembrolizumab/axitinib (mainly in 
patients with low PD- L1) is chosen. During the pandemic, 
ipilimumab/nivolumab is often being replaced by either 
pembrolizumab/axitinib, avelumab/axitinib, tivozanib or 
cabozantinib.
For two participants, none of the given criteria are rele-
vant for treatment decision, neither is the coronavirus 
pandemic. One expert prescribes ipilimumab/nivolumab, 
and the other prescribes pembrolizumab/axitinib irre-
spective of the situation.
During COVID-19, in patients already responding to 
an ICI/ICI combination 14 (37%) continue treatment as 
before. Twenty- four experts adapt their treatment in the 
following way: 32% (12 experts) continue ICI but extend 
cycle length, 16 (6) % hold one ICI but continue the other 
and 5% (2) hold treatment altogether. For the remaining 
participants (10%, 4), this is a case- by- case decision and 
could not be generalised (figure 3).
During the pandemic, in patients responding to ICI/
TKI 14 experts (37%) continue treatment as earlier, 13 
(34%) continue the TKI but extend ICI cycle length and 
6 (16%) continue TKI but hold ICI altogether. For the 
five remaining participants (13%), it is again a case- by- 
case decision. One expert holds TKI but continues ICI 
(figure 4).
An overview of all treatment recommendations is 
depicted in figure 5.
DISCUSSION
This is the first report on mccRCC systemic treatment 
modifications facing the COVID-19 pandemic. We 
performed an online survey among medical oncologists 
and urologists with expertise in kidney cancer treatment.
During a 12- day period, 48% of experts answered the 
survey. The majority of participants regard IMDC risk cate-
gory and patient fitness as relevant for decision- making, 
while only a minority also takes PD- L1 status into account. 
Two experts chose treatment irrespective of these factors. 
The use of IMDC risk category as distinction complies 
with international guidelines (eg, ESMO,18 NCCN19). 
Nevertheless, some drugs or drug combinations can be 
considered across all IMDC risk groups. Concerning 
patient fitness, it has been shown that elderly patients 
experience more adverse events than their younger 
counterparts when receiving targeted therapy of mRCC 
and this may be more pronounced when using combi-
nation treatment.20 The discordance among experts 
concerning use of PD- L1 expression for treatment selec-
tion may be explained by the fact that a post- hoc anal-
ysis of CheckMate 214 showed longer OS and a higher 
overall response rate (ORR)with ipilimumab/nivolumab 
than with sunitinib among intermediate- risk and poor- 
risk patients across tumour PD- L1 expression levels.13 
Though, partial responders and complete responders to 
ipilimumab/nivolumab both had higher baseline tumour 
PD- L1 expression than non- responders.21
Most common recommendations for treatment modi-
fications in response to the coronavirus pandemic are 
avoidance of one or two ICI and use of a TKI monotherapy 
instead: half the participants abstain from using ipili-
mumab/nivolumab for fit and intermediate/poor- risk 
patients. Some choose pembrolizumab/axitinib instead, 
and one- third opt for a TKI monotherapy with sunitinib, 
pazopanib, tivozanib and cabozantinib. For patients 
Figure 1 Preferred treatment choice in fit, IMDC 
favourable risk patients outside and during the COVID-19 
pandemic. IMDC, International Metastatic Renal Cell 
Carcinoma Database Consortium.
Figure 2 Preferred treatment choice in fit and unfit, IMDC 
intermediate/poor- risk patients outside and during the 
COVID-19 pandemic. IMDC, International Metastatic Renal 
Cell Carcinoma Database Consortium.
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responding to ICI/ICI, more than 50% of experts modify 
the treatment regimen by either extending cycle length, 
holding one ICI or even both. Similarly, for patients 
responding to ICI/TKI the majority of experts extend 
cycle length or only continue TKI or ICI. Some physicians 
decide on a case- by- case basis.
In addition to therapy modifications, some experts 
observe patients with asymptomatic disease and attempt 
to postpone treatment initiation in the current situation.
There are early data from China on the high COVID-19 
lethality rate of patients with an active cancer diagnosis: 
in this admittedly small retrospective case study, cancer 
patients showed deteriorating conditions and poor 
outcomes.22 An Italian study assessing the case fatality of 
COVID-19 found that among 355 patients who died and 
underwent detailed chart review, 72 (20%) had active 
cancer.23 Importantly, at this time it remains unclear 
whether patients with mccRCC are at higher risk of 
COVID-19 infection. The published data may represent 
a selection bias in which patients with COVID-19 and 
cancer are more likely to be hospitalised.24 It is possible 
that anticancer treatment itself poses additional risks in 
inducing an immune response and causing overlapping 
toxicities. Cancer is usually associated with a blunted 
immune status, characterised by overexpressed immuno-
suppressive cytokines, suppressed induction of proinflam-
matory danger signals, impaired dendritic cell maturation 
and enhanced functional immunosuppressive leucocyte 
populations.25 Drugs blocking the PD-1/PD- L1 interac-
tion may on the one hand enhance CD8 T- cell response 
and thereby decrease viral load, on the other hand they 
can exaggerate primary T- cell response and worsen acute 
infections.26 27
Apart from possible negative interference of ICI in 
the pathogenesis of COVID-19, controversies about 
SARS- CoV-2 and anticancer treatment with ICI are also 
Figure 3 Treatment adaptation during COVID-19 pandemic in patients responding to ICI/ICI. ICI, immune checkpoint 
inhibitor.
Figure 4 Treatment adaptation during COVID-19 pandemic in patients responding to TKI/ICI. ICI, immune checkpoint 
inhibitor; TKI, tyrosine kinase inhibitor.
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driven by concerns about potential overlap between 
the coronavirus- related interstitial pneumonia and 
lung toxicity from anti- PD-1/PD- L1 agents.28 Outside 
the pandemic, the overall incidence rate of ICI- related 
pneumonitis ranges from 2.5%–5% with anti- PD-1/
PD- L1 monotherapy to up to 7%–10% with cytotoxic 
t- lymphocyte- associated protein 4 (CTLA-4)/anti- PD-1 
combination therapy in trial participants and likely the 
rate is significantly higher in the real- world setting.29 To 
our knowledge, there is currently no data on the pneu-
monitis rate since the onset of the pandemic.
Interestingly, data from Thoracic Cancers International 
COVID-19 Collaboration presented during the 2020 
American Society of Clinical Oncology Virtual Scientific 
Program suggests that prior administration of chemo-
therapy as unique modality or in combination with ICI is 
associated with increased risk of death in patients treated 
for COVID-19, while immunotherapy and TKI are not.30
In addition to the apprehension of direct adverse drug 
effects, reasons for mccRCC treatment modifications 
entail efforts to maintain physical distancing and reduce 
hospital visits. In this line, participants may choose TKI 
monotherapy in favourable risk patients and omit an ICI 
altogether or postpone its use until after the pandemic.
Several physicians suggest reducing the frequency of 
radiological assessment of treatment status or treatment 
response. Some experts put favourable risk patients on 
active surveillance instead of starting active treatment. And 
some participants offer best supportive care to patients 
with IMCD poor risk and PS≥2. We would like to point to 
the recent update of KEYNOTE-426: the hazard ratio for 
pembrolizumab/axitinib versus sunitinib with respect to 
OS in patients with IMDC favourable risk is 1.06 (95% CI, 
0.60–1.86) after a median follow- up of 27 months.31 This 
could support the argument of starting a TKI and adding 
the ICI drug when the pandemic subsides. The data need 
to be interpreted with caution as it is a subgroup analysis.
Nivolumab monotherapy is active in treatment- naïve 
mccRCC across all IMDC risk groups. However, only a 
minority of patients could be rescued by the addition of 
ipilimumab at the time of disease progression.32 Hence, 
compromising drug exposure in the initial treatment phase 
when an ICI/ICI combination is chosen needs careful 
balancing.
What is apparent from this survey: most experts feel 
unease in continuing treatment in mccRCC patients as 
earlier. This pandemic is an unprecedented situation and 
the degree of impact on each health system is variable as 
the infection struck countries at different times and may 
have caused resource constraints.33 Also, national prepa-
ration and coping strategies were manifold.34 35 Hence, it 
is no surprise that attitudes towards mccRCC treatment 
choices diverge. Some participants clearly state that they 
have not changed anything in their practice as of yet due 
to the lack of data and uncertainty regarding the interfer-
ence of ICI and SARS- CoV-2 and vice versa.
There are several limitations to this analysis. A bias was 
introduced through selection of survey recipients. In addi-
tion, a physician with a case load of only 0–10 patients per 
year may not be considered a medical expert on RCC. 
However, we believe that international collaboration in 
large phase 3 trials and/or databases may be a qualifica-
tion per se. Due to the small number of responses, the 
conclusions may not be representative and do not gather 
Figure 5 Overview of all treatment recommendations. Left column: decision criteria; middle column: outside COVID-19 
and right column: during COVID-19. Ave/axi, avelumab/axitinib; cabo, cabozantinib; ipi/nivo, ipilimumab/nivolumab; PD- L1, 
programmed death- ligand 1; pembro/axi, pembrolizumab/axitinib; sun or paz, sunitinib or pazopanib; tivo, tivozanib.
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opinions from all regions of the world. For most questions 
only one answer could be selected, preventing participants 
from choosing several options. In drafting our survey, we 
focused on patients in imminent need of systemic treat-
ment and therefore did not include active surveillance or 
best supportive care. Nevertheless, some physicians specifi-
cally mentioned these as preferred options.
There is also an ethical dimension of forgoing optimal 
treatment and many questions remain open. Should 
patients continue to receive mccRCC therapy, which has 
been proven to have the best long- term outcome? Or 
should physicians refrain from using active drugs with the 
presumed risk of aggravating COVID-19 and rendering 
patients in need of intensive care? Furthermore, in case 
of shortage of ventilators, presence of a chronic cancer 
will probably have impact on treatment allocation.36
In summary, no solid recommendation can be given of 
withholding ICI drugs. We would rather propose a careful 
decision- making process for every individual patient, 
weighing all short- term and long- term pros and cons. Our 
aim is to highlight the challenges within the management 
of mccRCC patients, where life expectancy and quality of 
life have been improved with novel anticancer therapies 
such as immunotherapy.
A study on the impact of major non- pharmaceutical 
interventions across 11 European countries for the period 
from the start of COVID-19 until 4 May 2020, when lock-
downs started to be lifted, estimates that measures have 
been sufficient to drive the reproduction number below 
1, achieve epidemic control and avert about 3.1 million 
deaths.37 Yet, far from reaching herd immunity, there is 
a real risk of a second COVID-19 wave.38 This raises the 
question on how physicians anticipate such a scenario 
and prepare for it. In many settings precautions taken 
during the initial phase of the pandemic, such as phys-
ical distancing and wearing masks, remain in place. In 
addition, real- world data from international collaborative 
projects such as ESMO- CoCARE and the COVID-19 and 
Cancer Consortium (CCC19) cohort study may hopefully 
make it possible to rapidly accumulate knowledge, which 
will allow to disseminate information and guidance for 
patients and physicians in the future.39
With this manuscript, we hope not only to gather valu-
able opinions from experts in the field, but also to stimu-
late discussion of the theoretical and practical rationales 
of mccRCC treatments during the coronavirus pandemic 
and to show the scarce current level of evidence and the 
varying consequences thereof. We also want to raise ques-
tions most urgently needed to be addressed in the future:
Further investigation is warranted on the interplay of 
ICI and viral infections, outcome of cancer patients with 
SARS- CoV-2 and whether treatment modifications during 
pandemic alter long- term mccRCC patient outcome.
CONCLUSION
In this online survey among medical experts treating 
mccRCC, a shift away from use of ipilimumab/nivolumab 
was shown in response to the COVID-19 pandemic and 
increased use of TKI monotherapy. In patients responding 
to established therapies with ICI/ICI or ICI/TKI combi-
nations, most participants modify the treatment regimen 
by either extending cycle length, holding one ICI or even 
both. However, strategies in response to SARS- CoV-2 
differ substantially. It is crucial to find a balance between 
delivering high quality and efficacious treatment while 
limiting exposure to coronavirus and possible overlap-
ping toxicities due to systemic cancer treatment.
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